Browse the evidence

Tirzepatide use is associated with a significantly increased incidence of adverse reactions, particularly gastrointestinal issues like nausea and diarrhea, which are dose-dependent.

Be prepared for potential side effects when starting Tirzepatide. Nausea and diarrhea are common, especially when you first start or increase the dose. These symptoms often improve over time. Starting at a lower dose (2.5mg) and gradually increasing can help your body adjust. Most people find the side effects manageable.

Obesity is a complex chronic disease driven by biological, behavioral, and environmental factors, not merely a result of personal irresponsibility or lack of willpower.

Stop blaming yourself or others for obesity. It is a chronic disease with biological roots, not a moral failing. Seek healthcare providers who treat it as such, focusing on health outcomes rather than just weight loss.

Obesity is a causal factor for many types of cancer, including colorectal, endometrial, kidney, and postmenopausal breast cancer.

Maintaining a healthy weight reduces your risk of developing several common cancers, including colorectal, kidney, and postmenopausal breast cancer.

Fat-free mass-adjusted total and basal energy expenditure peaks at approximately 50% above adult levels around 1 year of age, then declines to adult baseline levels by age 20, remaining stable through age 60 before declining in older adults.

Your body's energy needs change predictably as you age. You burn significantly more energy relative to your size as a toddler (peaking around age 1) than as an adult. As you age from 20 to 60, your metabolic rate (adjusted for size) stabilizes. After 60, it declines. Do not assume your metabolic rate is constant or scales linearly with your weight; use age- and size-specific estimates for nutritional planning rather than simple weight-based ratios.

Different methods of measuring muscle hypertrophy (e.g., ultrasound, DXA, MRI, biopsy) often yield poorly correlated results, making it difficult to determine if true hypertrophy has occurred using a single metric.

Do not rely on a single measurement tool to judge your progress. Ultrasound, DXA, and MRI measure different things (thickness, lean mass, volume) and may not correlate with each other or with actual strength gains. If you are tracking progress, use multiple metrics (strength, visual, maybe one imaging modality) and understand that 'size' is a complex, multi-component adaptation.

Obese individuals with a normal metabolic profile (MHO) have significantly higher risks of heart failure, respiratory diseases, and all-cause mortality compared to non-obese individuals with a normal metabolic profile.

If you have obesity, do not assume you are 'healthy' just because your blood pressure and sugars are normal. You still face higher risks of heart failure and lung disease than someone who is not obese. Weight management is recommended for all people with obesity, regardless of their current metabolic profile, to lower these risks.

PGC-1α is a central regulator of exercise-induced mitochondrial biogenesis, but it is not strictly obligatory as biogenesis can still occur in its absence due to biological redundancy.

While PGC-1α is a key protein involved in building mitochondria, you don't need to worry about 'activating' it specifically. It is naturally upregulated by the stress of exercise. The fact that your body has redundant pathways means that as long as you challenge your muscles with endurance or high-intensity exercise, your body will find a way to build mitochondria, even if one specific pathway is less active.

Obesity increases the risk of estrogen-receptor-positive (ER+) breast cancer in postmenopausal women through the 'obesity-inflammation-aromatase axis,' where visceral fat produces estrogen via the enzyme aromatase.

For postmenopausal women, carrying extra weight around the middle is dangerous because fat cells act like small hormone factories. They convert other hormones into estrogen, which fuels the growth of many breast cancers. Losing weight reduces this local estrogen production and the inflammation that drives it, directly lowering your risk of developing estrogen-positive breast cancer.

GLP-1 receptor agonists reduce body weight primarily through central actions that induce satiety, rather than by increasing energy expenditure.

GLP-1 medications help you lose weight by making you feel full, not by boosting your metabolism. New oral versions exist, so you don't necessarily need injections.

Obesity is an independent, chronic non-communicable disease that directly causes cardiovascular disease through pathophysiological mechanisms including insulin resistance, endothelial dysfunction, and inflammation, rather than merely amplifying other risk factors.

Stop viewing obesity as just a lifestyle choice or a minor risk factor. It is a chronic disease with specific biological mechanisms (like inflammation and hormonal imbalance) that directly damage your heart and blood vessels. This means you deserve and need medical treatment, not just willpower-based advice, to manage it effectively and prevent heart disease.

GIP is the predominant incretin hormone in humans responsible for the majority of the incretin effect on postprandial insulin secretion, although its insulinotropic action is impaired in type 2 diabetes due to receptor downregulation.

Your body naturally produces GIP, which is the main hormone helping your pancreas release insulin after eating. In type 2 diabetes, this GIP signal gets weaker because the receptors on your insulin-producing cells become less sensitive. This is why treatments that target both GIP and GLP-1 receptors are often more effective than targeting GLP-1 alone.

In type 2 diabetes, the insulinotropic effect of GIP is significantly reduced or absent, primarily due to hyperglycemia-induced downregulation and degradation of the GIP receptor (GIPR) on beta cells.

In type 2 diabetes, your body still makes GIP, but your insulin cells stop listening to it because high blood sugar damages the receptors. This is reversible: lowering your blood sugar with medication or lifestyle changes can restore your body's natural ability to respond to GIP.

Bariatric surgery significantly reduces all-cause mortality and mortality from specific chronic diseases (diabetes, CAD, cancer) compared to non-surgical management.

Bariatric surgery not only helps you lose weight but significantly extends your life expectancy by reducing the risk of death from heart disease, diabetes, and cancer. This mortality benefit is unique to surgical weight loss and is not seen with lifestyle-induced weight loss.

GLP1R agonists (like liraglutide) suppress food intake by acting on LepRbGlp1r neurons, but this pathway alone is insufficient for significant body weight loss.

GLP-1 drugs like liraglutide work partly by activating a specific brain pathway (LepRbGlp1r) that tells you to eat less. However, this pathway alone doesn't account for all the weight loss, meaning other brain areas are also involved. This suggests these drugs are complex and work on multiple levels.

SGLT2 inhibitors reduce cardiovascular risk (specifically heart failure) independently of, or partially mediated by, the modest weight loss achieved.

SGLT2 inhibitors are prescribed for diabetes, but they also significantly lower the risk of heart failure. This benefit is linked to the modest weight loss and metabolic changes the drug causes. Even if your blood sugar control doesn't change drastically, your heart health may improve.

Using assumed or estimated menstrual cycle phases (e.g., calendar-based counting) instead of direct biochemical verification (e.g., LH surge, progesterone levels) produces invalid and unreliable data in sport-related research.

Do not use calendar-based methods or apps to assign menstrual cycle phases in research or applied practice without biochemical verification. To accurately determine phases (e.g., follicular vs. luteal), you must measure biological markers such as urinary luteinizing hormone (LH) surges and serum/saliva progesterone levels. Relying on calendar counting alone is scientifically invalid due to high inter- and intra-individual variability in ovulation timing and the prevalence of subtle menstrual disturbances.

Low-carbohydrate diets do not increase total energy expenditure (TEE) compared to high-carbohydrate diets when analyzed according to pre-registered protocols and accounting for energy conservation laws.

If you are trying to lose weight, switching to a low-carbohydrate diet will not give you a metabolic advantage in terms of burning more calories at rest or during activity compared to a high-carbohydrate diet, provided you eat the same number of calories. Focus on maintaining a caloric deficit rather than macronutrient composition for energy expenditure benefits.

Training status (years of experience) and sex do not significantly improve the predictive accuracy of dose-response models for resistance training outcomes.

You do not need to drastically change your core training variables (load, volume) based solely on your sex or years of training experience. Focus on matching load to your specific performance goal.

GLP-1 receptor agonists do not significantly increase the overall risk of cardiac arrhythmias (atrial fibrillation, atrial flutter, ventricular arrhythmias, or sudden cardiac death) in patients with type 2 diabetes or obesity compared to controls.

For patients with Type 2 Diabetes or Obesity, GLP-1 medications (like Ozempic, Trulicity, or Wegovy) are generally safe regarding heart rhythm. While they may slightly increase your resting heart rate, large studies show they do not increase the risk of serious heart rhythm problems like atrial fibrillation or ventricular arrhythmias compared to other treatments. However, those with very high BMI or on high doses should be monitored for ventricular arrhythmias.

Bariatric surgery is not first-line therapy for women of reproductive age hoping to conceive quickly due to risks of nutrient deficiencies and the required 1-2 year delay before pregnancy.

Avoid bariatric surgery if you plan to get pregnant soon. It requires a 1-2 year wait and can cause vitamin deficiencies that harm the baby. Use weight loss medications instead.

Ketogenic diets are not recommended for Type 1 Diabetes or Gestational Diabetes due to safety concerns, lack of long-term data, and potential risks of DKA and fetal harm.

Do not use a ketogenic diet for Type 1 Diabetes or Gestational Diabetes. The risks of Diabetic Ketoacidosis (DKA) and potential harm to fetal development outweigh any potential glycemic benefits. Follow standard medical advice for these conditions.

Elevated plasma levels of endotrophin, the C-terminal cleavage product of collagen type VI alpha 3 (COL6A3), causally increase the risk of coronary artery disease, acting as a primary mediator linking obesity to cardiometabolic disease.

Obesity increases the risk of heart disease partly by raising levels of a specific protein fragment called endotrophin. This fragment is created when body fat increases, specifically from abdominal subcutaneous fat. The good news is that losing body fat reduces these levels. Therefore, weight loss interventions that reduce abdominal adiposity are likely to lower this specific biological risk factor for coronary artery disease.

Dapagliflozin (10 mg daily) improves cardiometabolic outcomes in patients hospitalized for myocardial infarction, regardless of diabetes status, by reducing the risk of heart failure hospitalization and death.

If you have had a heart attack, even if you don't have diabetes, taking dapagliflozin (10 mg daily) alongside your standard heart medications can significantly improve your recovery outcomes. It reduces the risk of future heart failure hospitalizations and death. The benefit is seen regardless of your diabetes status.

Bempedoic acid (180 mg daily) reduces major adverse cardiovascular events (MACE) in high-risk patients who are unable or unwilling to take statins, primarily by lowering LDL cholesterol and reducing coronary revascularization needs.

If you have high cholesterol and a history of heart disease but cannot take statins due to side effects, bempedoic acid (180 mg daily) is an effective alternative. It lowers LDL cholesterol and significantly reduces your risk of heart attack, stroke, and the need for coronary procedures. It is taken once daily.